



DOCKET No.: SSBC-0001 (121300.00003)

JFW
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hu, Fang, et al.,
Serial No.: 10/766,307
Filed: January 28, 2004
Group: NA
For: THERAPY FOR PRIMARY AND METASTATIC CANCER

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

CERTIFICATE OF MAILING UNDER 37 CFR 1.8: I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on October 26, 2004.

M. Alfird

Signature

M. ALFIRD

Typed or Printed name of person signing Certificate

FIRST SUPPLEMENTAL TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Applicant certifies under 37 C.F.R. § 1.97(d)(2)(1) that the references contained in the information disclosure statement filed herewith were cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement.

Respectfully submitted,
JACKSON WALKER L.L.P.

T. Ling Chwang
T. Ling Chwang
Registration No. 33,590

October 26, 2004

Date:

JACKSON WALKER L.L.P.
2435 North Central Expressway, Suite 600
Richardson, Texas 75080
Tel: (972) 744-2919
Fax: (972) 744-2909



OCT 29 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete If Known	
		Application Number	10/766,307
		Filing Date	January 28, 2004
		First Named Inventor	Hu, et al.,
		Group Art Unit	
Examiner Name			
Sheet	1	of	2 Sheets
Attorney Docket Number			SSBC-0001 (121300.00002)

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	1.	WO 02/053711	07-11-2002	Holm	Entire Document	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



+

PATENTS TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE
Form 1449A/PTO**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	2	of	2 Sheets	Attorney Docket Number	SSBC-00001 (121300.0003)
-------	---	----	----------	------------------------	--------------------------

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	2.	HAVIV YS, Blackwell JL, Li H, Wang M, Lei X, Curiel DT. Heat shock and heat shock protein 70i enhance the oncolytic effect of replicative adenovirus. Cancer Res. 2001 Dec 1;61(23):8361-5.			
	3.	RIES S, Korn WM. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer. 2002 Jan 7;86(1):5-11.			
	4.	KRUYT FA, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther. 2002 Mar 1;13(4):485-95.			
	5.	FALK MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia. 2001 Jan-Feb;17(1):1-18.			
	6.	International Search Report, International Application No. PCT/US 04/002330 September 8, 2004			

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.